IL1B and colitis: Because we cannot treat mice earlier with peripherally administered anti-α4β7 or anti-MAdCAM-1 antibodies as they will alter the degree of colitis [50–53], we therefore used a strategy of blocking IL-1β with an ICV infusion of the IL-1 receptor antagonist (IL-1ra) from day 2.